Welcome to PsychU!

Virtual Event – Current Guidelines & Unmet Needs In The Treatment Of Agitation Associated With Alzheimer’s Dementia

Loading Events

Thank You For Attending Today’s Webinar

Please tell us what you thought about today’s presentation by taking the survey below:

Virtual Event – Current Guidelines & Unmet Needs In The Treatment Of Agitation Associated With Alzheimer’s Dementia

This is a Virtual Live Event for PsychU members in Connecticut, New Jersey, and New York City, NY.

Individualized and multimodal treatment plans are recommended for patients with Alzheimer’s disease and Agitation associated with Alzheimer’s Dementia (AAD). There is a need for better identification of AAD. There is also a need for approved pharmacological treatments that have proven and favorable benefit: risk profiles to reduce symptoms and ultimately improve burden to caregivers and healthcare.

In this discussion, current treatment guidelines, assess risk/benefit profile, and discuss unmet needs of AAD treatment will be reviewed.

Featuring

Jehan-Marino

Jehan Marino, PharmD, BCPP (OPDC)

Clinical & Scientific Director

Alyssa-Weers

Alyssa Weers, PharmD (OPDC)

Clinical & Scientific Liaison

Speakers Alyssa Weers PharmD and Jehan Marino PharmD, BCPP are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources